5th Annual Immuno-Oncology BD&L and Investment Forum.

Date:May 31, 2019

Venue:Waldorf Astoria Chicago Hotel, Chicago


About The 5th Annual Immuno-Oncology Forum

The 5th Annual Immuno-Oncology BD&L and Investment Forum is designed to bring together thought leaders from cancer research institutes, patient advocacy groups, pharma and biotech to facilitate partnering, funding and investment. We expect over 250 delegates and around 30 presentations by listed and private biotechnology companies seeking licensing & investment.

Plenary & Therapeutic Sessions Highlight:

-        Industry Roundtable

-        Pharma-Bio Dealmaking Panel

-        Revised Strategies for Advanced Therapeutics Panel

-        Latest Advances in Cell & Gene Therapies Panel

-        China-US Partnering & Investment Panel

-        Innovation Panel

-        Investor Discussion

Echo Hindle-Yang, Founder & CEO at MSQ Ventures is invited to join in the discussion of [China-US Partnering & Investment Panel]. It’s our great pleasure to invite you to participate in the 5th Annual Immuno-Oncology BD&L and Investment Forum.

China-US Partnering & Investment Panel

Co-Chaired by:

Guillaume Vignon, SVP BD, BeiGene, Ltd.

Helen Chen, MD and Head of China Life Sciences, L.E.K. Consulting 


Echo Hindle-Yang, Founder & CEO, MSQ Ventures

John Xu, Co-Founder & CEO, Jemincare Therapeutics Corp.

Ji Li, Venture Partner, Lilly Asia Ventures

Yuwan Liu, Founding Partner, BOHE Angel Fund

May Wang, SVP, Head of BD & Strategic Alliances, Hutchison China MediTech Ltd.